Patients who had negative baseline Bcl-2 in PB and BM will not undergo further treatment after radiotherapy; they will not repeat Bcl-2 during subsequent follow-up visits.

Patients who had positive baseline Bcl-2 in PB and / or BM and become negative after local radiotherapy will not undergo further treatment.

Patients who had positive baseline Bcl-2 in PB and / or BM and remain positive after local radiotherapy get Ofatumumab (8 weekly infusion of 1000 mg total dose).
Patients Bcl-2 negativized either after radiotherapy or after Ofatumumab, who became Bcl-2 positive during the follow-up monitoring will be treated/retreated with Ofatumumab 8 weekly infusions at the conventional dose of 1000 mg; Bcl-2 monitoring will be continued subsequently according to the program.In case of persistent positive PCR after Ofatumumab the treatment will not be repeated.

Follicular Lymphoma, Grade 1

Follicular Lymphoma, Grade 2

Follicular Lymphoma Grade 3A

OFATUMUMAB

Ospedale SS. Antonio e Biagio e Cesare Arrigo

Ematologia Azienda Ospedaliera Policlinico

Azienda Ospedaliera Caravaggio

A.O. Spedali Civili

IRCCS Casa Sollievo Della Sofferenza

IRCCS San Martino - IST

A.O. Niguarda

Azienda Ospedaliera S. Gerardo Di Monza

Osp. S. Maria delle Croci

A.O. Bianchi - Melacrino - Morelli

Polo Pontino

Ospedale S. Luigi Gonzaga,

Ospedale Mauriziano

Ospedale Civile di Mirano

ULSS5 UOC Medicina Generale Ospedale Valdagno

Centro di riferimento Oncologico Oncologia Medica A

Ospedale della Versilia USL12 - UOC Medicina - Sezione Ematologia

A.O. Universitaria Ospedale Vittorio Emanuele E Ferrarotto Di Catania

UO Ematologia PO Vito Fazzi

Ospedale di Matera

Area Vasta Romagna e IRST

Ospedali Riuniti Papardo

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Ospedale S. Raffaele

Istituto Europeo Oncologico

Ospedale Maggiore IRCCS-Dipartimento di Ematologia

Ospedale San Gennaro

S.C.D.U Ematologia Azienda Ospedaliero Universitaria Maggiore

U.O. Complessa di Ematologia Ospedale di Parma

IRCCS Policlinico S. Matteo di Pavia

Azienda Ospedaliera Di Perugia - Ospedale S. Maria Della Misericordia -

Ematologia e Centro Trapianti

Ausl Di Piacenza

Azienda Ospedaliero Universitaria Pisana U.O. Ematologia

AO Santa Maria Nuova

Ausl Di Rimini

Ematologia Ospedale S.Camillo Forlanini

Ematologia e Trapianto Istituto Regina Elena IFO

Policlinico Umberto I - Università "La Sapienza" - Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia

Ospedale civile DH oncologico

Policlinico Le Scotte Clinica Ematologica

SC Oncoematologia con autotrapianto AO Santa Maria

A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino

A.O.U. Citta della Salute e della Scienza di Torino

"MIRO" Molecularly Oriented Immuno-radio-therapy

"MIRO" (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab

The proportion of Bcl-2 negativization after Ofatumumab treatment will be estimated by the proportion, and its confidence interval, of residual Bcl-2 positive cases after radiotherapy, which will became negative after Ofatumumab treatment

Clinical response rate will be evaluated by the proportion and its confidence interval of patients achieving overall response (OR) complete response (CR) and partial response (PR).

Progression Free Survival (PFS) is defined as the length of time between the date of registration and the earliest date of disease progression or death due to any cause; If the patients doesn't not have a documented date of progression or death, the PFS will be censored at the date of last adequate assessment. Relapse Free Survival (RFS) is defined as the length of time between the achievement of Complete Remission (CR) and Relapse of disease

Relapse Free Survival (RFS) is defined as the length of time between the achievement of Complete Remission (CR) and Relapse of disease

Fondazione Italiana Linfomi ONLUS

prumnopitys

抗真菌藥

antifungal

prumnopitys/抗真菌藥

"MIRO" Molecularly Oriented Immuno-radio-therapy

科學支持的最完整的草藥數據庫